Cited by 141Acute Myeloid Leukemia ResearchRetinoids in leukemia and cellular processesAcute Lymphoblastic Leukemia research

The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.

Fludarabine and cytosine are less effective than standard ADE chemotherapy in high-risk acute myeloid leukemia, and addition of G-CSF and ATRA are not beneficial: results of the MRC AML-HR randomized trial

Milligan, Donald W., Wheatley, Keith, Littlewood, Timothy, Craig, Jenny I. O., Burnett, Alan K., for the NCRI Haematological Oncology Clinical Studies Group·2006·Blood

DOI 10.1182/blood-2005-10-4202

Open this paper in CoChat — free account

Abstract

The optimum chemotherapy schedule for reinduction of patients with high-risk acute myeloid leukemia (relapsed, resistant/refractory, or adverse genetic disease) is uncertain. The MRC AML (Medical Research Council Acute Myeloid Leukemia) Working Group designed a trial comparing fludarabine and high-dose cytosine (FLA) with standard chemotherapy comprising cytosine arabinoside, daunorubicin, and etoposide (ADE). Patients were also randomly assigned to receive filgrastim (G-CSF) from day 0 until neutrophil count was greater than 0.5 × 109/L (or for a maximum of 28 days) and all-trans retinoic acid (ATRA) for 90 days. Between 1998 and 2003, 405 patients were entered: 250 were randomly assigned between FLA and ADE; 356 to G-CSF versus no G-CSF; 362 to ATRA versus no ATRA. The complete remission rate was 61% with 4-year disease-free survival of 29%. There were no significant differences in the CR rate, deaths in CR, relapse rate, or DFS between ADE and FLA, although survival at 4 years was worse with FLA (16% versus 27%, P = .05). Neither the addition of ATRA nor G-CSF demonstrated any differences in the CR rate, relapse rate, DFS, or overall survival between the groups. In conclusion these findings indicate that FLA may be inferior to standard chemotherapy in high-risk AML and that the outcome is not improved with the addition of either G-CSF or ATRA.

Integrity signals

Registry

Crossref · 10.1182/blood-2005-10-4202

Cites

50 of 50 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Intensive Postremission Chemotherapy in Adults with Acute Myeloid Leukemia
Mayer, R. J., Davis, R. B., Schiffer, C. A., Berg, D. T., Powell, B. L., Schulman, P., Omura, G. A., Moore, J. O., McIntyre, O. R., & Frei, E. (1994) · New England Journal of Medicine · doi:10.1056/nejm199410063311402 · Cited by 1,427
2000 Update of Recommendations for the Use of Hematopoietic Colony-Stimulating Factors: Evidence-Based, Clinical Practice Guidelines
Ozer, H., Armitage, J. O., Bennett, C. L., Crawford, J., Demetri, G. D., Pizzo, P. A., Schiffer, C. A., Smith, T. J., Somlo, G., Wade, J. C., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.20.3558 · Cited by 1,044
High expression of bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy
Campos, L., Rouault, J., Sabido, O., Oriol, P., Roubi, N., Vasselon, C., Archimbaud, E., Magaud, J., & Guyotat, D. (1993) · Blood · doi:10.1182/blood.v81.11.3091.3091 · Cited by 783
Chemotherapy Compared with Autologous or Allogeneic Bone Marrow Transplantation in the Management of Acute Myeloid Leukemia in First Remission
Cassileth, P. A., Harrington, D. P., Appelbaum, F. R., Lazarus, H. M., Rowe, J. M., Paietta, E. M., Willman, C. L., Hurd, D. D., Bennett, J. M., Blume, K. G., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199812033392301 · Cited by 607
Randomised comparison of addition of autologous bone-marrow transplantation to intensive chemotherapy for acute myeloid leukaemia in first remission: results of MRC AML 10 trial
Burnett, A. K., Goldstone, A. H., Stevens, R., Hann, I. M., Rees, J. K. H., Gray, R. G., & Wheatley, K. (1998) · The Lancet · doi:10.1016/s0140-6736(97)09214-3 · Cited by 560
Self-citation
Prognostic Index for Adult Patients With Acute Myeloid Leukemia in First Relapse
Breems, D. A., van Putten, W. L. J., Huijgens, P. C., Ossenkoppele, G. J., Verhoef, G. E. G., Verdonck, L. F., Vellenga, E., de Greef, G. E., Jacky, E., der Lelie, J. V., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.06.027 · Cited by 510
Granulocyte–Macrophage Colony-Stimulating Factor after Initial Chemotherapy for Elderly Patients with Primary Acute Myelogenous Leukemia
Stone, R. M., Berg, D. T., George, S. L., Dodge, R. K., Paciucci, P. A., Schulman, P., Lee, E. J., Moore, J. O., Powell, B. L., & Schiffer, C. A. (1995) · New England Journal of Medicine · doi:10.1056/nejm199506223322503 · Cited by 447
Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial
Goldstone, A. H., Burnett, A. K., Wheatley, K., Smith, A. G., Hutchinson, R. M., & Clark, R. E. (2001) · Blood · doi:10.1182/blood.v98.5.1302 · Cited by 437
Self-citation
A simple, robust, validated and highly predictive index for the determination of risk‐directed therapy in acute myeloid leukaemia derived from the MRC AML 10 trial
Wheatley, K., Burnett, A. K., Goldstone, A. H., Gray, R. G., Hann, I. M., Harrison, C. J., Rees, J. K. H., Stevens, R., & Walker, H. (1999) · British Journal of Haematology · doi:10.1046/j.1365-2141.1999.01684.x · Cited by 432
Self-citation
Acute promyelocytic leukemia: evolving therapeutic strategies
Tallman, M. S., Nabhan, C., Feusner, J. H., & Rowe, J. M. (2002) · Blood · doi:10.1182/blood.v99.3.759 · Cited by 395
Effect of Priming with Granulocyte Colony-Stimulating Factor on the Outcome of Chemotherapy for Acute Myeloid Leukemia
Löwenberg, B., van Putten, W., Theobald, M., Gmür, J., Verdonck, L. F., Sonneveld, P., Fey, M. F., Schouten, H. C., de Greef, G. E., Ferrant, A., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa025406 · Cited by 385
The value of allogeneic bone marrow transplant in patients with acute myeloid leukaemia at differing risk of relapse: results of the UK MRC AML 10 trial
Burnett, A. K., Wheatley, K., Goldstone, A. H., Stevens, R., Hann, I. M., Rees, J. H. K., & Harrison, G. (2002) · British Journal of Haematology · doi:10.1046/j.1365-2141.2002.03724.x · Cited by 337
Self-citation
A Randomized, Double-Blind, Placebo-Controlled, Phase III Study of Filgrastim in Remission Induction and Consolidation Therapy for Adults With De Novo Acute Myeloid Leukemia
Heil, G., Hoelzer, D. F., Sanz, M. Á., Lechner, K., Yin, J. A. L., Papa, G. F. S., Noens, L., Szer, J., Ganser, A., O'Brien, C., et al. (1997) · Blood · doi:10.1182/blood.v90.12.4710 · Cited by 331
Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukemia during therapy.
Gandhi, V. V., Estey, E. H., Keating, M., & Plunkett, W. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.1.116 · Cited by 330
A Double-Blind Placebo-Controlled Trial of Granulocyte Colony-Stimulating Factor in Elderly Patients With Previously Untreated Acute Myeloid Leukemia: A Southwest Oncology Group Study (9031)
Godwin, J. E., Kopecky, K. J., Head, D. R., Willman, C. L., Leith, C. P., Hynes, H. E., Balcerzak, S. P., & Appelbaum, F. R. (1998) · Blood · doi:10.1182/blood.v91.10.3607 · Cited by 310
A Controlled Study of Recombinant Human Granulocyte Colony-Stimulating Factor in Elderly Patients after Treatment for Acute Myelogenous Leukemia
Dombret, H., Chastang, C., Fenaux, P., Reiffers, J. J., Bordessoule, D., Bouabdallah, R., Mandelli, F., Ferrant, A., Auzanneau, G., Tilly, H., et al. (1995) · New England Journal of Medicine · doi:10.1056/nejm199506223322504 · Cited by 308
Use of granulocyte colony-stimulating factor before, during, and after fludarabine plus cytarabine induction therapy of newly diagnosed acute myelogenous leukemia or myelodysplastic syndromes: comparison with fludarabine plus cytarabine without granulocyte colony-stimulating factor.
Estey, E. H., Thall, P. F., Andreeff, M., Beran, M., Kantarjian, H. M., O'Brien, S. M., Escudier, S. M., Robertson, L. E., Koller, C. A., & Kornblau, S. M. (1994) · Journal of Clinical Oncology · doi:10.1200/jco.1994.12.4.671 · Cited by 293
Randomized Phase II Study of Fludarabine + Cytosine Arabinoside + Idarubicin ± All-Trans Retinoic Acid ± Granulocyte Colony-Stimulating Factor in Poor Prognosis Newly Diagnosed Acute Myeloid Leukemia and Myelodysplastic Syndrome
Estey, E. H., Thall, P. F., Pierce, S. A., Cortes, J. E., Beran, M., Kantarjian, H. M., Keating, M. J., Andreeff, M., & Freireich, E. J. (1999) · Blood · doi:10.1182/blood.v93.8.2478.408k04_2478_2484 · Cited by 224
Postremission therapy in older patients with de novo acute myeloid leukemia: a randomized trial comparing mitoxantrone and intermediate-dose cytarabine with standard-dose cytarabine
Stone, R. M., Berg, D. T., George, S. L., Dodge, R. K., Paciucci, P. A., Schulman, P., Lee, E. J., Moore, J. O., Powell, B. L., Baer, M. R., et al. (2001) · Blood · doi:10.1182/blood.v98.3.548 · Cited by 211
Use of recombinant GM-CSF during and after remission induction chemotherapy in patients aged 61 years and older with acute myeloid leukemia: final report of AML-11, a phase III randomized study of the Leukemia Cooperative Group of European Organisation for the Research and Treatment of Cancer and the Dutch Belgian Hemato-Oncology Cooperative Group.
Löwenberg, B., Suciu, S., Archimbaud, E., Ossenkoppele, G. J., Verhoef, G. E. G., Vellenga, E., Wijermans, P., Berneman, Z. N., Dekker, A. W., Stryckmans, P. A., et al. (1997) · PubMed · doi:10.1182/blood.v90.8.2952 · Cited by 205
Treatment of relapsed and refractory acute myelogenous leukemia
Estey, E. (2000) · Leukemia · doi:10.1038/sj.leu.2401568 · Cited by 166
Fludarabine, cytarabine, G‐CSF and idarubicin (FLAG‐IDA) for the treatment of poor‐risk myelodysplastic syndromes and acute myeloid leukaemia
Parker, J. E., Pagliuca, A., Mijović, A., Cullis, J., Czepulkowski, B. H., Rassam, S. M. B., Samaratunga, I., Grace, R. J., Gover, P., & Mufti, G. J. (1997) · British Journal of Haematology · doi:10.1046/j.1365-2141.1997.4763281.x · Cited by 162
The relationship between bcl‐2 expression and response to chemotherapy in acute leukaemia
Maung, Z. T., MacLean, F. R., Reid, M. M., Pearson, A. D. J., Proctor, S. J., Hamilton, P. J., & Hall, A. G. (1994) · British Journal of Haematology · doi:10.1111/j.1365-2141.1994.tb04984.x · Cited by 160
A double-blind controlled study of granulocyte colony-stimulating factor started two days before induction chemotherapy in refractory acute myeloid leukemia. Kohseisho Leukemia Study Group [see comments]
Ohno, R., Naoe, T., Kanamaru, A., Yoshida, M., Hiraoka, A., Kobayashi, T., Ueda, T., Minami, S., MORISHIMA, Y., & Saito, Y. (1994) · Blood · doi:10.1182/blood.v83.8.2086.2086 · Cited by 153
A placebo-controlled study of recombinant human granulocyte-macrophage colony-stimulating factor administered during and after induction treatment for de novo acute myelogenous leukemia in elderly patients. Groupe Ouest Est Leucémies Aiguës Myéloblastiques (GOELAM).
Witz, F., Sadoun, A., Perrin, M. C., Berthou, C., Brière, J., Cahn, J.-Y. Y., Lioure, B., Witz, B., François, S., Desablens, B., et al. (1998) · PubMed · doi:10.1182/blood.v91.8.2722.2722_2722_2730 · Cited by 146
A double-blind controlled study of granulocyte colony-stimulating factor started two days before induction chemotherapy in refractory acute myeloid leukemia. Kohseisho Leukemia Study Group [see comments]
Ohno, R., Naoe, T., Kanamaru, A., et al. (1994) · Blood · doi:10.1182/blood.v83.8.2086.bloodjournal8382086 · Cited by 132
FLAG (fludarabine + high-dose cytarabine + G-CSF): an effective and tolerable protocol for the treatment of 'poor risk' acute myeloid leukemias.
Visani, G., Tosi, P., Zinzani, P. L., Manfroi, S., Ottaviani, E., Testoni, N., Clavio, M., Cenacchi, A., Gamberi, B., & Carrara, P. (1994) · PubMed · Cited by 128
Value of different modalities of granulocyte-macrophage colony-stimulating factor applied during or after induction therapy of acute myeloid leukemia.
Löwenberg, B., Boogaerts, M. A., Daenen, S. M. G. J., Verhoef, G. E. G., Hagenbeek, A., Vellenga, E., Ossenkoppele, G. J., Huijgens, P. C., Verdonck, L. F., der Lelie, J. V., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.12.3496 · Cited by 126
Allogeneic marrow transplantation during untreated first relapse of acute myeloid leukemia.
Clift, R. A., Buckner, C. D., Appelbaum, F. R., Schoch, G. H., Petersen, F. B., Bensinger, W., Sanders, J., Sullivan, K. M., Storb, R. F., & Singer, J. W. (1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.11.1723 · Cited by 123
Granulocyte-macrophage colony-stimulating factor associated with induction treatment of acute myelogenous leukemia: a randomized trial by the European Organization for Research and Treatment of Cancer Leukemia Cooperative Group.
Zittoun, R., Suciu, S., Mandelli, F., de Witte, T., Thaler, J., Stryckmans, P. A., Hayat, M., Peetermans, M. E., Cadiou, M., Solbu, G., et al. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.7.2150 · Cited by 120
A long-term follow-up report on allogeneic stem cell transplantation for patients with primary refractory acute myelogenous leukemia: impact of cytogenetic characteristics on transplantation outcome
Fung, H. C. H., Stein, A. S., Slovak, M. L., O'Donnell, M. R., Snyder, D., Cohen, S., Smith, D. D., Krishnan, A., Spielberger, R. T., Bhatia, R., et al. (2003) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2003.08.004 · Cited by 119
A multicentre, open, non‐comparative phase II study of a combination of fludarabine phosphate, cytarabine and granulocyte colony‐stimulating factor in relapsed and refractory acute myeloid leukaemia and de novo refractory anaemia with excess of blasts in transformation
Jackson, G. H., Taylor, P. R. A., Smith, G., Marcus, R. E., Smith, A. G., Chu, P., Littlewood, T. J., Duncombe, A. S., Hutchinson, M., Mehta, A. B., et al. (2001) · British Journal of Haematology · doi:10.1046/j.1365-2141.2001.02551.x · Cited by 110
Self-citation
The value of fludarabine in addition to ARA-C and G-CSF in the treatment of patients with high-risk myelodysplastic syndromes and AML in elderly patients
Ossenkoppele, G. J. (2003) · Blood · doi:10.1182/blood-2003-07-2195 · Cited by 110
A stratification system for evaluating and selecting therapies in patients with relapsed or primary refractory acute myelogenous leukemia [letter]
Estey, E. H., Kornblau, S. M., Pierce, S. A., Kantarjian, H. M., Beran, M., & Keating, M. J. (1996) · Blood · doi:10.1182/blood.v88.2.756.bloodjournal882756 · Cited by 109
Definition of refractoriness against conventional chemotherapy in acute myeloid leukemia: a proposal based on the results of retreatment by thioguanine, cytosine arabinoside, and daunorubicin (TAD 9) in 150 patients with relapse after standardized first line therapy.
Hiddemann, W., Martin, W. R., Sauerland, C., Heinecke, A., & Büchner, T. (1990) · PubMed · Cited by 107
The Treatment of Acute Myeloid Leukemia in First Relapse: A Comprehensive Review of the Literature
Leopold, L. H., & Willemze, R. (2002) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/1042819021000006529 · Cited by 104
Comparison of ‘sequential’ versus ‘standard’ chemotherapy as re‐induction treatment, with or without cyclosporine, in refractory/relapsed acute myeloid leukaemia (AML): results of the UK Medical Research Council AML‐R trial
Yin, J. A. L., Wheatley, K., Rees, J. K. H., Burnett, A. K., & Party, T. U. M. A. L. W. (2001) · British Journal of Haematology · doi:10.1046/j.1365-2141.2001.02785.x · Cited by 99
Self-citation
Serum interleukin-10 levels in patients with advanced gastrointestinal malignancies
Vita, F. D., Orditura, M., Galizia, G., Romano, C. P., Infusino, S., Auriemma, A., Lieto, E., & Catalano, G. (1999) · Cancer · doi:10.1002/(sici)1097-0142(19991115)86:10 · Cited by 93
Direct evidence for the participation of bcl-2 in the regulation by retinoic acid of the Ara-C sensitivity of leukemic stem cells.
Hu, Z., Minden, M. D., & McCulloch, E. A. (1995) · PubMed · Cited by 72
Efficacy of granulocyte colony‐stimulating factor in the treatment of acute myelogenous leukaemia: a multicentre randomized study
Usuki, K., Urabe, A., Masaoka, T., Ohno, R., Mizoguchi, H., Hamajima, N., Miyazaki, T., Niitsu, Y., Yoshida, Y., MIURA, A. B., et al. (2002) · British Journal of Haematology · doi:10.1046/j.1365-2141.2002.03251.x · Cited by 68
Fludarabine, cytosine arabinoside, granulocyte‐colony stimulating factor with or without idarubicin in the treatment of high risk acute leukaemia or myelodysplastic syndromes
Virchis, A. E., Koh, M., Rankin, P., Mehta, A. B., Potter, M. N., Hoffbrand, A. V., & Prentice, H. G. (2003) · British Journal of Haematology · doi:10.1046/j.1365-2141.2003.04728.x · Cited by 67
Phase-II trial of idarubicin, fludarabine, cytosine arabinoside, and filgrastim (Ida-FLAG) for treatment of refractory, relapsed, and secondary AML
Steinmetz, H. T., Schulz, A., Staib, P., Scheid, C., Glasmacher, A. G., Neufang, A., Franklin, J. G., Tesch, H., Diehl, V., & Wickramanayake, P. D. (1999) · Annals of Hematology · doi:10.1007/s002770050541 · Cited by 62
Impact of cytogenetics on the prognosis of adults with de novo AML in first relapse
Weltermann, A., Fonatsch, C., Haas, O. A., Greinix, H., Kahls, P., Mitterbauer, G., Jaeger, U., Kainz, B., Geissler, K. H., Valent, P., et al. (2003) · Leukemia · doi:10.1038/sj.leu.2403243 · Cited by 55
FLAG is a Useful Regimen for Poor Prognosis Adult Myeloid Leukaemias and Myelodysplastic Syndromes
Nokes, T., Johnson, S. A., Harvey, D., & Goldstone, A. H. (1997) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428199709068275 · Cited by 44
Splenic abscess and sickle cell disease
Al-Salem, A. H., Qaisaruddin, S., Jam'a, A. A., Al-Kalaf, J., & Elbashier, A. M. (1998) · American Journal of Hematology · doi:10.1002/(sici)1096-8652(199806)58:2 · Cited by 41
Guidelines on the use of colony‐stimulating factors in haematological malignancies
Pagliuca, A., Carrington, P. A., Pettengell, R., Rule, S. A., & Keidan, J. (2003) · British Journal of Haematology · doi:10.1046/j.1365-2141.2003.04546.x · Cited by 40
Regulation by retinoic acid and hydrocortisone of the anthracycline sensitivity of blast cells of acute myeloblastic leukemia.
Yang, G., Minden, M. D., & McCulloch, E. A. (1994) · PubMed · Cited by 32
FLAG-idarubicin and allogeneic stem cell transplantation for Ph-positive ALL beyond first remission
Deane, M., Koh, M., Foroni, L., Galactowicz, G., Hoffbrand, A. V., Lawler, M., Secker‐Walker, L. M., & Prentice, H. G. (1998) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1701521 · Cited by 23
[A randomized double-blind controlled study of recombinant human granulocyte colony-stimulating factor in patients with neutropenia induced by consolidation chemotherapy for acute myeloid leukemia. (rG.CSF clinical study group)].
Takeshita, A., Ohno, R., HIRASHIMA, K., Toyama, K., Okuma, M., Saito, H., Ikeda, Y., Tomonaga, M., & Asano, S. (1995) · PubMed · Cited by 14
Does All-Transretinoic Acid (ATRA) Have a Role in Non-APL Acute Myeloid Leukaemia?: Results from 1666 Patients in Three MRC Trials.
Burnett, A. K., Milligan, D. W., Hills, R. K., Goldstone, A. H., Prentice, A., Wheatley, K., Webb, D. K. H., & Gibson, B. E. S. (2004) · Blood · doi:10.1182/blood.v104.11.1794.1794 · Cited by 6
Self-citation

Research works printed but not linked: 1

Visani G, Tosi P, Zinzani PL, et al. FLAG: an effective and tolerable protocol for the treatment of “poor-risk” acute myeloid leukemia. Leukemia. 1994;8: 1842-1846.

Sorted by citations

Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet
Döhner, H., Estey, E. H., Amadori, S., Appelbaum, F. R., Büchner, T., Burnett, A. K., Dombret, H., Fenaux, P., Grimwade, D. J., Larson, R. A., et al. (2009) · Blood · doi:10.1182/blood-2009-07-235358 · Cited by 3,438
Self-citation
Induction of cell cycle entry eliminates human leukemia stem cells in a mouse model of AML
Saito, Y., Uchida, N., Tanaka, S., Suzuki, N., Tomizawa-Murasawa, M., Sone, A., Najima, Y., Takagi, S., Aoki, Y., Wake, A., et al. (2010) · Nature Biotechnology · doi:10.1038/nbt.1607 · Cited by 433
Retinoic acid receptors: From molecular mechanisms to cancer therapy
di Masi, A., Leboffe, L., De Marinis, E., Pagano, F., Cicconi, L., Rochette-Egly, C., Lo-Coco, F., Ascenzi, P., & Nervi, C. (2015) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2014.12.003 · Cited by 403
The leukaemia stem cell: similarities, differences and clinical prospects in CML and AML
Vetrie, D. L. P., Helgason, G. V., & Copland, M. (2020) · Nature reviews. Cancer · doi:10.1038/s41568-019-0230-9 · Cited by 365
How I treat refractory and early relapsed acute myeloid leukemia
Thol, F. R., Schlenk, R. F., Heuser, M., & Ganser, A. (2015) · Blood · doi:10.1182/blood-2014-10-551911 · Cited by 307

See all 141

Authors: Milligan, D. W., Wheatley, K., Littlewood, T., Craig, J. I. O., Burnett, A. K., & for the NCRI Haematological Oncology Clinical Studies Group
Affiliations: John Radcliffe Hospital (GB)
ORCID: Wheatley, Keith
Burnett, Alan K.
Venue: Blood
Publisher: American Society of Hematology
Published: 2006-06-15
Volume: 107
Issue: 12
Pages: 4614-4622
ISSN: 0006-4971 (ISSN-L)
1528-0020
DOI: 10.1182/blood-2005-10-4202
OpenAlex: W1984229644
Cited by: 141
References: 49
Citations by year: 2026: 2 · 2025: 3 · 2024: 4 · 2023: 8 · 2022: 4 · 2021: 10 · 2020: 5 · 2019: 5 · 2018: 8 · 2017: 6 · 2016: 11 · 2015: 10 · 2014: 7 · 2013: 8 · 2012: 8
FWCI: 5.26
Type: journal article
Language: en
Open access: closed
Locations: Blood (publishedVersion)
PubMed (publishedVersion)
University of Birmingham Research Portal (University of Birmingham) (submittedVersion)
Topics: Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Retinoids in leukemia and cellular processes
Health Sciences › Medicine › Hematology › Acute Lymphoblastic Leukemia research
Keywords: high-risk acute myeloid leukemia, fludarabine, cytarabine, daunorubicin, etoposide, filgrastim, granulocyte colony-stimulating factor, all-trans retinoic acid, reinduction chemotherapy, complete remission, disease-free survival, relapse
MeSH terms: Filgrastim, Adolescent, Adult, Aged, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Cytarabine, Daunorubicin, Etoposide, Female, Humans, Male, Middle Aged, Recombinant Proteins, Remission Induction, Retrospective Studies, Risk Factors, Tretinoin, Leukemia, Myeloid, Acute, Survival Rate, Granulocyte Colony-Stimulating Factor, Treatment Outcome, Disease-Free Survival

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Fludarabine and cytosine are less effective than standard ADE chemotherapy in high-risk acute myeloid leukemia, and addition of G-CSF and ATRA are not beneficial: results of the MRC AML-HR randomized trial

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks